Lanny J Rosenwasser

Summary

Affiliation: National Jewish Medical and Research Center
Country: USA

Publications

  1. ncbi request reprint Treatment of allergic rhinitis
    Lanny J Rosenwasser
    National Jewish Medical and Research Center and the University of Colorado Health Science Center, Denver, Colorado 80206, USA
    Am J Med 113:17S-24S. 2002
  2. ncbi request reprint Anti-CD23 monoclonal antibody, lumiliximab, inhibited allergen-induced responses in antigen-presenting cells and T cells from atopic subjects
    Jill A Poole
    National Jewish Medical and Research Center, University of Colorado Health Sciences Center, Division of Allergy and Clinical Immunology, Department of Medicine, Denver, USA
    J Allergy Clin Immunol 116:780-8. 2005
  3. ncbi request reprint Anti-CD23
    Lanny J Rosenwasser
    Division of Allergy and Immunology, Department of Medicine, National Jewish Medical and Research Center University of Colorado Health Sciences Center, Denver, CO, USA
    Clin Rev Allergy Immunol 29:61-72. 2005
  4. ncbi request reprint A 49-year-old male with intractable dyspnea, wheeze, and cough
    Christopher A Bates
    National Jewish Medical and Research Center, Denver, Colorado 80205, USA
    Ann Allergy Asthma Immunol 91:20-5. 2003
  5. ncbi request reprint Allergic asthma and an anti-CD23 mAb (IDEC-152): results of a phase I, single-dose, dose-escalating clinical trial
    Lanny J Rosenwasser
    University of Colorado Health Science Center and the Division of Allergy and Clinical Immunology, National Jewish Medical and Research Center, 1400 Jackson Street, Denver, CO 80206, USA
    J Allergy Clin Immunol 112:563-70. 2003
  6. ncbi request reprint Association of transforming growth factor-beta1 single nucleotide polymorphism C-509T with allergy and immunological activities
    Jianfeng Meng
    Division of Allergy and Clinical Immunology, Department of Medicine, National Jewish Medical and Research Center, Denver, CO 80206, USA
    Int Arch Allergy Immunol 138:151-60. 2005
  7. doi request reprint Treatment of patients with the hypereosinophilic syndrome with mepolizumab
    Marc E Rothenberg
    Division of Allergy and Immunology, Department of Pediatrics, Cincinnati Children s Hospital Medical Center, University of Cincinnati, Cincinnati, OH 45229, USA
    N Engl J Med 358:1215-28. 2008
  8. ncbi request reprint FCER2: a pharmacogenetic basis for severe exacerbations in children with asthma
    Kelan G Tantisira
    Channing Laboratory, Brigham and Women s Hospital, Boston, MA 02115, USA
    J Allergy Clin Immunol 120:1285-91. 2007
  9. ncbi request reprint The role of immunoglobulin E and immune inflammation: implications in allergic rhinitis
    Jill A Poole
    National Jewish Medical and Research Center, University of Colorado Health Sciences Center, Denver 80206, USA
    Curr Allergy Asthma Rep 5:252-8. 2005
  10. ncbi request reprint Targeting the IgE molecule in allergic and asthmatic diseases: review of the IgE molecule and clinical efficacy
    Jill A Poole
    National Jewish Medical and Research Center, University of Colorado Health Sciences Center, Denver 80206, USA
    J Allergy Clin Immunol 115:S376-85. 2005

Detail Information

Publications17

  1. ncbi request reprint Treatment of allergic rhinitis
    Lanny J Rosenwasser
    National Jewish Medical and Research Center and the University of Colorado Health Science Center, Denver, Colorado 80206, USA
    Am J Med 113:17S-24S. 2002
    ..Some of the newer oral antihistamines, such as cetirizine, desloratadine, and fexofenadine, have been shown to relieve the symptom of nasal congestion. Intranasal steroids are first-line therapy for patients with more severe symptoms...
  2. ncbi request reprint Anti-CD23 monoclonal antibody, lumiliximab, inhibited allergen-induced responses in antigen-presenting cells and T cells from atopic subjects
    Jill A Poole
    National Jewish Medical and Research Center, University of Colorado Health Sciences Center, Division of Allergy and Clinical Immunology, Department of Medicine, Denver, USA
    J Allergy Clin Immunol 116:780-8. 2005
    ..A novel anti-CD23 monoclonal antibody, lumiliximab, is a potential therapeutic antibody recently demonstrated to be safe in human beings...
  3. ncbi request reprint Anti-CD23
    Lanny J Rosenwasser
    Division of Allergy and Immunology, Department of Medicine, National Jewish Medical and Research Center University of Colorado Health Sciences Center, Denver, CO, USA
    Clin Rev Allergy Immunol 29:61-72. 2005
    ..Although the safety and clinical efficacy of Lumilixilab in allergic asthma and rhinitis require confirmation, the observed data imply that anti-CD23 is a promising candidate therapy option for future treatment of allergic diseases...
  4. ncbi request reprint A 49-year-old male with intractable dyspnea, wheeze, and cough
    Christopher A Bates
    National Jewish Medical and Research Center, Denver, Colorado 80205, USA
    Ann Allergy Asthma Immunol 91:20-5. 2003
  5. ncbi request reprint Allergic asthma and an anti-CD23 mAb (IDEC-152): results of a phase I, single-dose, dose-escalating clinical trial
    Lanny J Rosenwasser
    University of Colorado Health Science Center and the Division of Allergy and Clinical Immunology, National Jewish Medical and Research Center, 1400 Jackson Street, Denver, CO 80206, USA
    J Allergy Clin Immunol 112:563-70. 2003
    ..CD23, a cell-surface molecule, is involved in a variety of pathways likely to influence IgE production and inflammation in allergic disorders, such as allergic rhinitis and allergic asthma...
  6. ncbi request reprint Association of transforming growth factor-beta1 single nucleotide polymorphism C-509T with allergy and immunological activities
    Jianfeng Meng
    Division of Allergy and Clinical Immunology, Department of Medicine, National Jewish Medical and Research Center, Denver, CO 80206, USA
    Int Arch Allergy Immunol 138:151-60. 2005
    ..To further understand the mechanisms involved, the association of C-509T with allergy, T-lymphocyte proliferation and plasma TGFbeta1 concentration has been explored in a case-control study with allergic and non-allergic subjects...
  7. doi request reprint Treatment of patients with the hypereosinophilic syndrome with mepolizumab
    Marc E Rothenberg
    Division of Allergy and Immunology, Department of Pediatrics, Cincinnati Children s Hospital Medical Center, University of Cincinnati, Cincinnati, OH 45229, USA
    N Engl J Med 358:1215-28. 2008
    ..Although most patients have a response to corticosteroids, side effects are common and can lead to considerable morbidity...
  8. ncbi request reprint FCER2: a pharmacogenetic basis for severe exacerbations in children with asthma
    Kelan G Tantisira
    Channing Laboratory, Brigham and Women s Hospital, Boston, MA 02115, USA
    J Allergy Clin Immunol 120:1285-91. 2007
    ..Although inhaled corticosteroids (ICSs) generally protect against severe exacerbations in asthma, they may result in elevated IgE levels, which are associated with exacerbations...
  9. ncbi request reprint The role of immunoglobulin E and immune inflammation: implications in allergic rhinitis
    Jill A Poole
    National Jewish Medical and Research Center, University of Colorado Health Sciences Center, Denver 80206, USA
    Curr Allergy Asthma Rep 5:252-8. 2005
    ..Understanding the role of the IgE molecule is necessary to appreciate the development and use of novel therapies targeting its actions...
  10. ncbi request reprint Targeting the IgE molecule in allergic and asthmatic diseases: review of the IgE molecule and clinical efficacy
    Jill A Poole
    National Jewish Medical and Research Center, University of Colorado Health Sciences Center, Denver 80206, USA
    J Allergy Clin Immunol 115:S376-85. 2005
  11. ncbi request reprint Corticosteroid pharmacogenetics: association of sequence variants in CRHR1 with improved lung function in asthmatics treated with inhaled corticosteroids
    Kelan G Tantisira
    Channing Laboratory, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    Hum Mol Genet 13:1353-9. 2004
    ....
  12. ncbi request reprint Mechanisms of asthma
    William W Busse
    Allergy and Clinical Immunology, University of Wisconsin Department of Medicine, Madison, WI, USA
    J Allergy Clin Immunol 111:S799-804. 2003
    ..The contribution of genetics to asthma has been examined in a wide variety of studies, ranging from epidemiologic association and twin studies all the way to molecular analysis through microarray gene expression experiments...
  13. ncbi request reprint Efficacy and safety of budesonide and formoterol in one pressurised metered-dose inhaler in adults and adolescents with moderate to severe asthma: a randomised clinical trial
    Michael Noonan
    Allergy Associates Research Center, Portland, Oregon 97213, USA
    Drugs 66:2235-54. 2006
    ..The efficacy and safety of the combination of budesonide and formoterol delivered via dry powder inhaler (DPI) is well documented...
  14. ncbi request reprint Placebo response in asthma: a robust and objective phenomenon
    Margaret E Kemeny
    University of California, San Francisco, Calif, USA
    J Allergy Clin Immunol 119:1375-81. 2007
    ..Nevertheless, mind-body links and placebo responsivity in asthma are widely believed to exist...
  15. ncbi request reprint Risk assessment in anaphylaxis: current and future approaches
    F Estelle R Simons
    Department of Pediatrics and Child Health, University of Manitoba, Winnipeg, Canada, and Department of Respiratory Medicine, Brighton General Hospital, Belfast, UK
    J Allergy Clin Immunol 120:S2-24. 2007
    ....
  16. ncbi request reprint 5. Genetics of hypersensitivity
    John W Steinke
    University of Virginia Health System, Charlottesville, VA 22908 1355, USA
    J Allergy Clin Immunol 111:S495-501. 2003
    ..It is to be hoped that they will also define new targets for the next generation of asthma and allergy therapeutic agents...
  17. ncbi request reprint Asthma therapies and Churg-Strauss syndrome
    Craig M Lilly
    Pulmonary and Critical Care Division, Brigham and Women s Hospital, Boston, MA 02115, USA
    J Allergy Clin Immunol 109:S1-19. 2002
    ..Early recognition and immunosuppressive therapy are the keystones of successful treatment of this rare disorder...